Get the Stockscreener App
2.71
1.09%
-0.03
After Hours:
2.69
-0.02
-0.74%
Cerus Corp stock is traded at $2.71, with a volume of 1.73M.
It is down -1.09% in the last 24 hours and up +39.69% over the past month.
Cerus Corp is a biomedical products company focused on the field of blood transfusion safety. The INTERCEPT Blood System is designed to reduce the risk of transfusion-transmitted infections by inactivating a broad range of pathogens such as viruses, bacteria, and parasites. The company sells its INTERCEPT platelet and plasma systems in the United States of America, Europe, the Commonwealth of Independent States countries, the Middle East, and selected countries in other regions around the world. The firm continues to operate in only one segment: Blood safety, and generates revenue from the same.
See More
Previous Close:
$2.74
Open:
$2.74
24h Volume:
1.73M
Relative Volume:
0.78
Market Cap:
$543.00M
Revenue:
$216.56M
Net Income/Loss:
$-9.57M
P/E Ratio:
-54.53
EPS:
-0.0497
Net Cash Flow:
$-1.22M
1W Performance:
+15.81%
1M Performance:
+39.69%
6M Performance:
+67.28%
1Y Performance:
+116.80%
1-Day Range:
$2.69
$2.81
1-Week Range:
$2.34
$2.87
52-Week Range:
$1.15
$3.15
Cerus Corp Stock (CERS) Company Profile
Name
Cerus Corp
Sector
Industry
Phone
(925) 288-6000
Address
1220 CONCORD AVENUE, CONCORD, CA
Compare CERS vs ABT, SYK, MDT, BSX, EW
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CERS
Cerus Corp
|
2.71 | 549.01M | 216.56M | -9.57M | -1.22M | -0.0497 |
ABT
Abbott Laboratories
|
87.41 | 152.88B | 45.13B | 6.28B | 7.38B | 3.5895 |
SYK
Stryker Corp
|
316.48 | 120.18B | 25.27B | 3.34B | 4.57B | 8.6334 |
MDT
Medtronic Plc
|
78.60 | 100.34B | 35.48B | 4.64B | 5.41B | 3.582 |
BSX
Boston Scientific Corp
|
57.78 | 84.95B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
85.78 | 47.91B | 6.30B | 1.07B | 1.09B | 1.8406 |
Cerus Corp Stock (CERS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-12-24 | Initiated | Craig Hallum | Buy |
| Jan-20-23 | Downgrade | BTIG Research | Buy → Neutral |
| Jan-17-23 | Downgrade | Stephens | Overweight → Equal-Weight |
| Oct-08-20 | Resumed | BTIG Research | Buy |
| Jun-16-20 | Resumed | Cantor Fitzgerald | Overweight |
| Feb-26-20 | Initiated | BTIG Research | Buy |
| Nov-13-19 | Upgrade | BTIG Research | Neutral → Buy |
| Aug-28-19 | Initiated | Stifel | Buy |
| Aug-23-19 | Resumed | Stephens | Overweight |
| Jan-05-18 | Resumed | Cantor Fitzgerald | Overweight |
| Dec-08-17 | Resumed | BTIG Research | Neutral |
| Jul-07-16 | Resumed | Cantor Fitzgerald | Buy |
| Dec-17-15 | Downgrade | Wedbush | Outperform → Neutral |
| May-02-14 | Reiterated | MLV & Co | Buy |
| Apr-24-13 | Reiterated | Cantor Fitzgerald | Buy |
| Mar-15-13 | Reiterated | MLV & Co | Buy |
| Apr-17-12 | Initiated | Cantor Fitzgerald | Buy |
| Feb-29-12 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Nov-10-11 | Reiterated | MLV & Co | Buy |
| Jun-03-11 | Initiated | Wedbush | Outperform |
| Mar-04-11 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Mar-09-10 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Aug-26-09 | Upgrade | Avondale | Mkt Perform → Mkt Outperform |
View All
Cerus Corp Stock (CERS) Latest News
What’s Fueling New Momentum Across Penny Stock Markets? - Kalkine Media
Q1 2026 Cerus Corp Earnings Call Transcript - GuruFocus
Cerus Corporation (CERS) Gets Upgraded to Buy Post Q1 by BTIG - Insider Monkey
Cerus Corporation (CERS) Q1 2026 Earnings: EPS Surprises to the Upside as Loss NarrowsCrowd Breakout Signals - Newser
Cerus Corp stock (US1570851014): turnaround hopes after sharp rally in blood safety specialist - AD HOC NEWS
Are NYSE Penny Stocks Showing Mixed Financial Strength? - Kalkine Media
Cerus Corp stock (US1570851014): blood safety specialist in focus after Q1 2026 update - AD HOC NEWS
Cerus Corp stock (US1570851014): blood safety specialist back in focus after latest business update - AD HOC NEWS
Cerus Corp stock (US1570851014): Recent 2.21% gain amid mixed signals - AD HOC NEWS
Cerus Is Finding Its Next Gear In Blood Safety - Finimize
Vivek Jayaraman Sells 16,667 Shares of Cerus (NASDAQ:CERS) Stock - MarketBeat
Cerus corp COO Vivek Jayaraman sells $50,001 in common stock By Investing.com - Investing.com Australia
Cerus corp COO Vivek Jayaraman sells $50,001 in common stock - Investing.com
Cerus (CERS) COO sells 16,667 shares in planned 10b5-1 trade - Stock Titan
Cerus Momentum Builds Amid Healthcare Innovation Buzz On Nasdaq Composite - Kalkine Media
Cerus (NASDAQ:CERS) Sees Unusually-High Trading Volume Following Analyst Upgrade - MarketBeat
Cerus Company Profile & Introduction - Moomoo
Cerus (NASDAQ:CERS) Upgraded by Zacks Research to Hold Rating - MarketBeat
Cerus Corporation Reports First Quarter 2026 Financial Results - HarianBasis.co
Cerus (NASDAQ:CERS) Upgraded by Wall Street Zen to Buy Rating - MarketBeat
Cerus Corporation Q1 2026 SEC Filing: Financial Statements, Risk Factors, and Management Discussion - Minichart
[144] CERUS CORP SEC Filing - Stock Titan
Insider sale filings: CERS (NASDAQ: CERS) reports restricted stock dispositions - Stock Titan
CERS Upgraded by BTIG -- Price Target Announced at $4.00 - GuruFocus
Cerus (NASDAQ:CERS) Reaches New 12-Month High After Better-Than-Expected Earnings - MarketBeat
Let's uncover which stocks are experiencing notable gaps during today's session. - ChartMill
CERSCerus Corp Stock Price and Quote - Finviz
BTIG Research Upgrades Cerus (NASDAQ:CERS) to "Buy" - MarketBeat
Cerus Corporation Q1 2026 Earnings Call Summary - Yahoo Finance
Cerus Corporation (NASDAQ:CERS) Q1 2026 Earnings Call Transcript - Insider Monkey
Cerus Corp (CERS) Q1 2026 Earnings Call Highlights: Strong Reven - GuruFocus
Cerus (NASDAQ:CERS) Issues Quarterly Earnings Results, Beats Estimates By $0.02 EPS - MarketBeat
Is Cerus (CERS) 8.6% Undervalued After Q1 2026 Earnings Beat? EP - GuruFocus
Cerus Q1 Earnings Call Highlights - MarketBeat
Cerus (NASDAQ: CERS) grows Q1 2026 revenue and sharply cuts net loss - Stock Titan
Cerus Q1 2026 Earnings Call Transcript - Benzinga
Earnings call transcript: Cerus Corporation Q1 2026 beats EPS forecast - Investing.com
Cerus Corp 1Q 2026: Revenue $59.9M, EPS $(0.01) — 10-Q Summary - TradingView
Cerus Corporation (CERS) Stock Rises on Q1 2026 Earnings - Quiver Quantitative
Cerus Corp (NASDAQ:CERS) Surges on Strong Q1 Beat and Raised Guidance - ChartMill
Cerus: Q1 Earnings Snapshot - San Francisco Chronicle
Cerus Reports Q1 2026 Revenue $59.9M, Product Revenue Up 24% and Raises 2026 Product Guidance - TradingView
Cerus Corporation (NASDAQ: CERS) lifts 2026 outlook after strong Q1 results - Stock Titan
Blood safety company Cerus lifts 2026 forecast after 24% product-sales jump - Stock Titan
Cerus signs four-year supply deal with French blood service - Investing.com
Cerus signs four-year supply deal with French blood service By Investing.com - Investing.com Canada
Cerus wins 4-year deal with French blood network serving 330,000 units - Stock Titan
Cerus Corporation Announces New, Four-Year Supply Agreement with French Blood Establishment for INTERCEPT Blood System - Yahoo Finance
CERS SEC FilingsCerus 10-K, 10-Q, 8-K Forms - Stock Titan
Cerus (CERS) to Release Earnings on Thursday - MarketBeat
[ARS] CERUS CORP SEC Filing - Stock Titan
Cerus Corp Stock (CERS) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.22%
1.41%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):